Improved procedure for cancer-related erectile dysfunction

April 12, 2019

Melbourne surgeons have modified a minimally invasive technique to help men regain erectile function lost after prostate cancer surgery.

The surgery had a 71 per cent success rate with two participants achieving their first erection in 12 years.

Published in European Urology, the study is the first to report this procedure, which can restore the ability to have satisfactory sexual intercourse and improve sexual quality of life in men with erectile dysfunction following a nerve-sparing or non-nerve-sparing radical prostatectomy.

Of the 8500 Australian men with prostate cancer who have a radical prostatectomy each year, at least 70 per cent experience erectile dysfunction. Many are unaware of the risk or suffer in silence.

Treatment usually involves injections or a prosthesis, which can have side effects. The improved technique, pioneered in Brazil, uses a nerve removed from the patient's leg to restore erectile function.

Microsurgeon and University of Melbourne Department of Surgery Professor, Christopher Coombs, and Monash Medical Centre urologist, Mr David Dangerfield, developed the new procedure.

Professor Coombs, who is also the paper's senior author, said these early results were promising. Those who could achieve erections again were extremely grateful - as were their partners.

"We looked at sexual quality of life before and after. Regaining erectile function had a significant impact on quality of life and the way the men felt about themselves," Professor Coombs said.

"When they walk back in after 12 months you know if it's worked - they're smiling and so are their partners. They think it's great."

Radical prostatectomy can injure the penis' nerves to the spongy tissue, the corpora cavernosa, which are responsible for initiating an erection.

The review followed 17 patients aged under 70 with severe or moderate post-prostatectomy erectile dysfunction, who had a sexual partner and undetectable PSA (Prostate Specific Antigen) levels.

Between March 2015 and October 2017, the men, whose median age was 64, underwent 'end-to-side' surgery to remove the sural nerve from the leg and graft it to the side of the larger femoral nerve in the thigh. New nerve fibres then grew along the sural nerve graft into the corpora cavernosa of the penis.

All patients tolerated the 2.5-4-hour procedure and were discharged after an overnight hospital stay. Erectile function was restored in three men within six months and nine within 12 months, a total of 71 per cent.

After a year, all 12 with restored erectile function had clinically relevant improvements in their sexual function, and 83 per cent were less bothered by their symptoms. Of the 12, seven did not require drugs to achieve erectile function "sufficient for satisfactory sexual penetration".

There were no side effects besides two minor wound infections and three patients with temporary quadriceps weakness which lasted one week.

End-to-side nerve grafting was first described in a medical journal in 1903 but is not known to have been used again until 1992, when

Brazilian surgeon Fausto Viterbo began using it generally.

In 2017, Professor Viterbo reported on his use of nerve grafting to restore erectile function in men after prostatectomy. Professor Coombs and Mr Dangerfield simplified and potentially improved his technique (see below).

Lead author and NHMRC research fellow Jeanette Reece, of the University of Melbourne School of Population and Global Health's Centre for Epidemiology and Biostatistics, independently evaluated patient outcomes.

"The patients all had improved quality of life," Dr Reece said. "Two achieved erections after being unable to for 12 years. This procedure is also much less invasive than the traditional alternative of penile prosthesis."

How the technique works

The latest 'end-to-side' technique to restore erectile function sees two sural nerves removed from the legs, where they are not required for full leg function. One end of the nerve graft is attached to the thigh's femoral nerve, the other into the corpus cavernosa, which is the spongy part of the penis.

The sural nerve then acts as a scaffolding (conduit), similar to an extension cord, to deliver regenerating nerve fibres from the femoral nerve to the corpus cavernosa. After around 12 months, new nerve endings in the corpus cavernosa release neurotransmitter (acetylcholine) which help initiate an erection.

Brazilian Professor Fausto Viterbo reported on end-to-side nerve grafting to restore erectile function in 2017. The Melbourne surgeons' innovation is to remove sensory nerves grafts to induce minor injury to the femoral nerve to stimulate regeneration.

The new procedure aims to provide more axons (threadlike part of a nerve cell along which impulses are conducted) to the penis due to that partial injury (neurotomy) to the femoral nerve.
-end-


University of Melbourne

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.